Bristol-Myers to buy Celgene in industry-shaking $74B deal

Bristol-Myers Squibb will acquire Celgene in a $74 billion cash-and-stock deal that would recast the top ranks of the pharmaceutical industry, creating a powerful combined company with leading positions in immuno-oncology and the treatment of blood cancers